January 1, 2002Advances in Pulmonary Hypertension
Endothelin Receptor Antagonism: A New Era in the Treatment of Pulmonary Arterial Hypertension
Key result
Endothelin receptor antagonists like bosentan markedly and sustainably improve exercise capacity over placebo in PAH.
Why the study?
Abnormal increases in endothelin-1 production and decreased pulmonary clearance play a major pathogenetic role in pulmonary arterial hypertension, motivating development of endothelin receptor antagonists.
Does bosentan improve exercise capacity in patients with pulmonary arterial hypertension?
Population
Patients with pulmonary arterial hypertension
Comparison
Bosentan versus placebo
Design
Review of randomized, placebo-controlled, double-blind studies
Follow-up
Up to 22 months
Authors
Discussion
Loading...
Member takes
Implication
Supports endothelin pathway targeting in pulmonary hypertension; leaves open optimal patient selection for randomized confirmation.
Structured PICO
Does bosentan improve exercise capacity in patients with pulmonary arterial hypertension?
P
Population
Patients with pulmonary arterial hypertension
I
Intervention
Endothelin receptor antagonists (specifically bosentan)
C
Comparator
Placebo (in the context of the discussed trials)
O
Outcome
Exercise capacitysurrogate
Endothelin receptor antagonists like bosentan provide sustained improvements in exercise capacity for patients with pulmonary arterial hypertension.
Cite This Study
Channick et al. (2002) conducted a review in Pulmonary Arterial Hypertension. Endothelin receptor antagonists (e.g., bosentan) vs. Placebo was evaluated on Exercise capacity. Endothelin receptor antagonists such as bosentan provide marked and sustained improvement in exercise capacity for patients with pulmonary arterial hypertension.